Abstract:Small cell lung cancer (SCLC) that constitutes of 15-18% of all lung cancers is a highly lethal malignancy. The functional effects of long noncoding RNAs(lncRNAs) in cancer have been widely recognized. Long intergenic non-protein coding RNA 173(Linc00173) was first identified in SCLC, and was found to be involved in chemoresistance. We aimed to explore the regulatory mechanisms of Linc00173 using drug-resistant cell lines and human tissues. We used microarrays to compare expression profiles of lncRNAs in SCLC cell line and the drug-resistant subline and Linc00173 was identified. Linc00173 was examined in 60 SCLC patient samples by qRT-PCR assay. The functional roles of Linc00173 in SCLC were studied by overexpression and RNA interference approaches in vitro and in vivo. The localization of the genes were involved in competitive endogenous RNAs (ceRNAs) regulatory network was studied by separating cytoplasmic and nuclear RNA fractions from SCLC. Bioinformatic analysis, luciferase assays, RNA immunoprecipitation and pull-down assays were performed to elucidate the role of Linc00173 in mechanism of ceRNA. The positive Linc00173/Etk correlation was further verified by qRT-PCR assay and bivariate correlation analysis in clinical tissues and blood samples. We found that Linc00173 expression was significantly associated with chemoresistance and the shorter survival time in SCLC patients. Downregulation of Linc00173 expression could impair cell proliferation and increased cell sensitivity to anticancer drugs, while upregulation of Linc00173 promoted the proliferation and induced multidrug resistance both in vitro and in vivo. Linc00173 overexpression enhanced the expression of Etk through competitively ‘spongeing’ miRNA-218 resulting in the activation of STAT3. Particularly, the ceRNA regulatory network of above genes was occurred in nucleus. Finally, the positive Linc00173/Etk correlation was found in SCLC tissues and blood samples. Linc00173 was first identified to promote proliferation and chemoresistance of SCLC. It regulates levels of Etk by acting as ‘sponger ’of miR-218. These genes may be novel indices for clinical diagnosis of tumor growth and chemoresistance in SCLC.

LINC00173 silence and estrone supply suppress ER+ breast cancer by estrogen receptor α degradation and LITAF activation

Activation of ERβ Hijacks the Splicing Machinery to Trigger R-loop Formation in Triple-Negative Breast Cancer

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

Lnc-DC Promotes Estrogen Independent Growth and Tamoxifen Resistance in Breast Cancer

Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression

Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer

ETS-1-activated LINC01016 Over-Expression Promotes Tumor Progression Via Suppression of RFFL-mediated DHX9 Ubiquitination Degradation in Breast Cancers

Linc00152 Promotes Tumorigenesis by Regulating DNMTs in Triple-Negative Breast Cancer

UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.

Supplementary Data from Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression

LINC00092 Modulates Oxidative Stress and Glycolysis of Breast Cancer Cells Via Pyruvate Carboxylase-Mediated AKT/mTOR Pathway

Long Non-Coding RNA LINC00672 Contributes to P53 Protein-Mediated Gene Suppression and Promotes Endometrial Cancer Chemosensitivity

LncRNA LINP1 Confers Tamoxifen Resistance and Negatively Regulated by ER Signaling in Breast Cancer.

LINC00882, Transcriptionally Activated by CEBP-β and Post-Transcriptionally Stabilized by METTL14-mediated M6a Modification, Exerts Tumorigenesis by Promoting PABPC1-mediated Stabilization of ELK3 Mrna

LINC00882 , transcriptionally activated by CEBP-β and post-transcriptionally stabilized by METTL14-mediated m 6 A modification, exerts tumorigenesis by promoting PABPC1-mediated stabilization of ELK3 mRNA

LINC01572 promotes triple‐negative breast cancer progression through EIF4A3‐mediated β‐catenin mRNA nuclear exportation

Long noncoding RNA LINC00885 upregulates NCK1 to promote cell viability and migration of triple-negative breast cancer cells through sponging miR-654-3p

LINC00662 enhances cell progression and stemness in breast cancer by MiR-144-3p/SOX2 axis

P2.15-009 Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Functioning As a Competing Endogenous RNA to Regulate Etk Expression